W
Wen-Hsiang Chen
Researcher at Baylor College of Medicine
Publications - 39
Citations - 1489
Wen-Hsiang Chen is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Coronavirus & Neutralizing antibody. The author has an hindex of 14, co-authored 33 publications receiving 976 citations. Previous affiliations of Wen-Hsiang Chen include Boston Children's Hospital & University of Houston.
Papers
More filters
Journal ArticleDOI
The SARS-CoV-2 Vaccine Pipeline: an Overview.
TL;DR: It is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration.
Journal ArticleDOI
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
TL;DR: Analysis of published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19 finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD.
Journal ArticleDOI
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate
Wen-Hsiang Chen,Lanying Du,Shivali M. Chag,Cuiqing Ma,Nancy Tricoche,Xinrong Tao,Christopher A. Seid,Elissa M. Hudspeth,Sara Lustigman,Chien Te K. Tseng,Maria Elena Bottazzi,Peter J. Hotez,Bin Zhan,Shibo Jiang +13 more
TL;DR: It is found that RBD219-N1 exhibited high expression yield, and maintained its antigenicity and functionality, and more importantly, induced significantly stronger RBD-specific antibody responses and a higher level of neutralizing antibodies in immunized mice than RBD193-WT, RBD 193-N 1, R BD193-N3, or RBD 219-WT.
Journal ArticleDOI
Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.
Wen-Hsiang Chen,Shivali M. Chag,Mohan Vivekanandan Poongavanam,Amadeo B. Biter,Ebe A. Ewere,Wanderson C. Rezende,Christopher A. Seid,Elissa M. Hudspeth,Jeroen Pollet,Jeroen Pollet,C. Patrick McAtee,Ulrich Strych,Ulrich Strych,Maria Elena Bottazzi,Peter J. Hotez +14 more
TL;DR: A panel of characterization tests indicated that the process is reproducible and that the purified, tag-free RBD219-N1 protein has high purity and a well-defined structure and is therefore a suitable candidate for production under current Good Manufacturing Practice and future phase-1 clinical trials.
Posted ContentDOI
Recombinant Protein Vaccines, a Proven Approach Against Coronavirus Pandemics
TL;DR: This article summarized the current public information on the nature and on the development status of recombinant subunit antigens and adjuvants targeting SARS-CoV-2 infections.